Latest Sustainability News

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

Chilwa Minerals confirmed a significant niobium discovery at its Nakombe target, progressing with dual diamond rig drilling and advancing a NASDAQ listing application. Heavy mineral sands resource work continues alongside a new ionic clay rare earth program.

Centaurus Metals has secured a binding offtake deal with Glencore and attracted up to US$320 million in financing offers for its Jaguar Nickel Project, while advancing exploration and pilot testing at its Brazilian copper-gold and iron ore assets.

VBX Limited has more than doubled the Measured and Indicated Mineral Resource at its Wuudagu bauxite project to 131.9 million tonnes with improved grades, while also enhancing its Definitive Feasibility Study scope and securing additional funding.

Beach Energy’s Q3 FY26 output rose 7% quarter-on-quarter, led by a 174% surge in Perth Basin production following Waitsia Gas Plant compressor commissioning. The company also secured new Queensland acreage and greenlit the Moomba Central Optimisation project, though weather disruptions trimmed Cooper Basin output and prompted a production guidance cut.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

Golden Horse Minerals delivered robust drilling results at Southern Cross in Q1 2026, including visible gold at depth and strong shallow intercepts, supported by a healthy cash reserve of $39.3 million.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.